Previous Article | Next Article ![]()
Journal of Clinical Microbiology, November 1999, p. 3533-3539, Vol. 37, No. 11
bioMérieux, Inc., Hazelwood,
Missouri1; Department of Oral Medicine
and Oral Pathology, School of Dental Science and Dublin Dental
Hospital, Trinity College, University of Dublin, Dublin 2, Republic of
Ireland2; Mycotic Diseases Branch,
Division of Bacterial and Mycotic Diseases, National Center for
Infectious Diseases, Centers for Disease Control and Prevention,
Atlanta, Georgia3; and Wadsworth Center
for Laboratories and Research, New York State Department of Health,
Albany, New York4
Received 16 April 1999/Returned for modification 12 July
1999/Accepted 2 August 1999
Candida dubliniensis is a newly described species that
is closely related phylogenetically to Candida albicans and
that is commonly associated with oral candidiasis in human
immunodeficiency virus-positive patients. Several recent studies have
attempted to elucidate phenotypic and genotypic characteristics of use
in separating the two species. However, results obtained with simple phenotypic tests were too variable and tests that provided more definitive data were too complex for routine use in the clinical laboratory setting. The objective of this study was to determine if
reproducible identification of C. dubliniensis could be
obtained with commercial identification kits. The substrate reactivity profiles of 80 C. dubliniensis isolates were obtained by
using the API 20C AUX, ID 32 C, RapID Yeast Plus, VITEK YBC, and VITEK 2 ID-YST systems. The percentages of C. dubliniensis
isolates capable of assimilating or hydrolyzing each substrate were
compared with the percentages from the C. albicans profiles
in each kit's database, and the results were expressed as percent
C. dubliniensis and percent C. albicans. Any
substrate that showed >50% difference in reactivity was considered
useful in differentiating the species. In addition, assimilation of
methyl-
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Rapid Identification of Candida
dubliniensis with Commercial Yeast Identification
Systems
-D-glucoside (MDG), D-trehalose (TRE), and D-xylose (XYL) by the same isolates was
investigated by the traditional procedure of Wickerham and Burton
(L. J. Wickerham and K. A. Burton, J. Bacteriol. 56:363-371,
1948). At 48 h (the time recommended by the manufacturer for its
new database), we found that the assimilation of four carbohydrates in
the API 20C AUX system could be used to distinguish the species, i.e.,
glycerol (GLY; 88 and 14%), XYL (0 and 88%), MDG (0 and 85%), and
TRE (15 and 97%). Similarly, results with the ID 32 C system at
48 h showed that XYL (0 and 98%), MDG (0 and 98%), lactate (LAT;
0 and 96%), and TRE (30 and 96%) could be used to separate the two
species. Phosphatase (PHS; 9 and 76%) and
-D-glucosidase (23 and 94%) proved to be the most
useful for separation of the species in the RapID Yeast Plus system.
While at 24 h the profiles obtained with the VITEK YBC system
showed that MDG (10 and 95%), XYL (0 and 95%), and GLY (26 and 80%)
could be used to separate the two species, at 48 h only XYL (6 and
95%) could be used to separate the two species. The most useful
substrates in the VITEK 2 ID-YST system were TRE (1 and 89%), MDG (1 and 99%), LAT (4 and 98%), and PHS (83 and 1%). While the latter kit
was not yet commercially available at the time of the study, it would
appear to be the most valuable for the identification of C. dubliniensis. Although assimilation of MDG, TRE, and XYL proved
to be the most useful for species differentiation by the majority of
commercial systems, the results with these carbohydrates by the
Wickerham and Burton procedure were essentially the same for both
species, albeit following protracted incubation. Thus, it is the
rapidity of the assimilation achieved with the commercial systems that
allows the differentiation of C. dubliniensis from C. albicans.
*
Corresponding author. Mailing address: Dept. 015-B1/L3,
bioMérieux, Inc., 595 Anglum Rd., Hazelwood, MO 63042-2320. Phone: (314) 731-7456. Fax: (314) 731-7454. E-mail:
dave_pincus{at}na.biomerieux.com.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|